kras g12d degrader arv-806
Generic: KRAS G12D Degrader ARV-806
kras g12d degrader arv-806: developed by 1 company · 1 clinical trial tracked.
kras g12d degrader arv-806 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect kras g12d degrader arv-806 to ARVN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could kras g12d degrader arv-806 → ARVN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
KRAS G12D Mutation
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ARVINAS, INC. (ARVN) KRAS G12D Mutation | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806
Interventionalopen159 targetStarted 2025-05Completion 2026-1114 sites · United StatesArvinas Inc.
Frequently asked questions
Who is developing kras g12d degrader arv-806?
kras g12d degrader arv-806 is being developed by ARVINAS, INC..
How many clinical trials involve kras g12d degrader arv-806?
BioSniper tracks 1 clinical trial involving kras g12d degrader arv-806.